Fresenius Medical Care AG & Co. KGaA (FMS) is a publicly traded company in the Healthcare — Medical - Care Facilities industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support.
Is Fresenius Medical Care AG & Co. KGaA stock overvalued or undervalued in 2026?
Fresenius Medical Care AG & Co. KGaA (FMS) trades at 12.2× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At the decade median (16.0×) $30 (+31 %); at its sector median (30.4×) $56 (+150 %).
Kaplio overview: Fresenius Medical Care AG & Co. KGaA
Market cap $12B · 52 weeks $20 – $27 (14 % below the high) · P/E 12.2× · 2027 expected P/E 9.4× · Dividend 3.7 % · 4 years rising · Next earnings November 3, 2026 · expected EPS $0.65 · Closing price, Oct 28 · accounts published Aug 3.
- Valuation: P/E 12.2× (cheap).
- Business: ROIC 6 % (weak).
- Balance sheet: Net debt/EBITDA 2.7× (watch).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
At the decade median (16.0×) $30 (+31 %); at its sector median (30.4×) $56 (+150 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 7 pass
- R&D / Revenue 0.8 %, fails.
- 5y EPS growth 5.1 %, fails.
- Gross margin 25.6 %, fails.
- ROIC 6.2 %, fails.
- Net debt / EBITDA 2.7×, borderline.
- FCF / Net Income 173.3 %, passes.
- P/E vs own 10y history 12.2×, passes.
Against its peers (reference peers) — Fresenius Medical Care AG & Co. KGaA: P/E 12.2×; EV/EBITDA 5.8×; ROIC 6.2 %; $12.0B. DaVita Inc. (P/E 16.2×; EV/EBITDA 7.9×; ROIC 11.2 %; $11.7B), Encompass Health Corporation (P/E 19.9×; EV/EBITDA 10.0×; ROIC 13.4 %; $12.0B), The Ensign Group, Inc. (P/E 27.4×; EV/EBITDA 17.7×; ROIC 7.4 %; $10.7B).
Expensive or cheap against its last ten years?
P/E at each close: today 12.2× · median 16.0× · minimum 7.9× · maximum 25.6× · cheap below 14.3× · expensive above 19.9×. It has been cheaper than today only 16% of the time over its last ten years.
Dividend
solid · Yield 3.7 % ($0.78 per ADS in 2025) · Years raising it 4 · 5-year growth +12 % a year · Free cash flow coverage 4.9× · With $1,000 invested today you'd collect $36.80 a year ($3.07 a month).
Investor methods verdict
Would Buffett approve Fresenius Medical Care AG & Co. KGaA today?
The Buffett Method would not approve Fresenius Medical Care AG & Co. KGaA today: it fails its quality rules. Business quality: 68 out of 100 (price not included). Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Would Peter Lynch approve Fresenius Medical Care AG & Co. KGaA today?
The Lynch Method would wait for a better price for Fresenius Medical Care AG & Co. KGaA: P/E 12.2 with 5% growth; it asks that the P/E not exceed growth. Business quality: 83 out of 100 (price not included). Lynch classifies it as a stalwart. Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Profitability
| Return on Equity | 7.21% |
| Return on Invested Capital | 6.21% |
| Return on Assets | 3.00% |
| Gross Margin | 26.36% |
| Operating Margin | 10.69% |
| Net Margin | 4.83% |
Financial Health
| Debt / Equity | 0.87 |
| Current Ratio | 1.07 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 1.32 |
Price Performance
| 1 month | +1.03% |
| 3 months | -12.31% |
| Year-to-date | -5.54% |
| 1 year | -16.36% |
| 3 years | +34.65% |
| 5 years | -32.29% |
| 10 years | -44.55% |
Dividend History
Paid in the last 12 months: $0.8643 per share in 1 payments.
| Date | Amount |
|---|---|
| 2026-05-22 | $0.8643 |
| 2025-05-23 | $0.8150 |
| 2024-05-17 | $0.6341 |
| 2023-05-17 | $0.6181 |
| 2022-05-13 | $0.7093 |
| 2021-05-24 | $0.8338 |
| 2020-08-28 | $0.7073 |
| 2019-05-17 | $0.6551 |
| 2018-05-21 | $0.6320 |
| 2017-05-11 | $0.5137 |
Amounts adjusted for stock splits.
Related companies: TVTX · DVA · HCA · 0J1R.L · 0RPS.L · THC · EHC · 0I7E.L
Explore sector: Healthcare · Medical - Care Facilities
More sections of FMS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks